Tetra Therapeutics

Tetra works to restore clarity of thought. Our innovative compound is based on PDE enzymes, targeting Alzheimer's Disease, Fragile X, & traumatic brain injury.

[Tetra Therapeutics @TetraDiscovery]

Finalizamos nuestra última visita al paciente en la fase 2 del estudio PICASSO del medicamento BPN14770 de Tetra para la enfermedad de Alzheimer. Le enviamos un sincero agradecimiento a los pacientes que participaron y a sus cuidadores. #Alzheimers

[Tetra Therapeutics @TetraDiscovery]

We completed our last patient visit in the Phase 2 PICASSO study of Tetra’s BPN14770 drug for Alzheimer’s disease. Sending a heartfelt thank you to the patients who participated and their caregivers. #Alzheimers

[Tetra Therapeutics @TetraDiscovery]

@Tetra CEO, Mark Gurney was recently interviewed by Simon Wentworth @ThePharmaLetter. “Our lead compound is neuroprotective in preclinical models and has the potential to slow Alzheimer’s disease progression.”https://t.co/FjJN6Gd7Wo

[Tetra Therapeutics @TetraDiscovery]

Excellent panel discussion @BIOCEO on new approaches to late stage brain disease #Alzheimer’s. Thank you to Jason Pitts Principal, Private Equity, at @Sofinnova for moderating. Tetra CEO, Mark Gurney, pictured below.

[Tetra Therapeutics @TetraDiscovery]

We are headed to #BIOCEO in New York next week to participate in a panel on late stage brain disorder pipelines and unmet needs. Hope to see you there.

[Tetra Therapeutics @TetraDiscovery]

We are grateful for the Fragile X community and want to thank the patients participating in our Phase 2 trial. Enrollment is now complete! #FragileX

[Tetra Therapeutics @TetraDiscovery]

“This is a totally novel concept about the causation of Alzheimer’s disease. These data suggest that the inflammatory process in the body may trigger disease process in the brain.” Listen to Bio Report’s Podcast with @TetraCEO, Mark Gurney. https://t.co/HkYVYHvgv0

[Tetra Therapeutics @TetraDiscovery]

Looking back at 2019, it has been a big year for @Tetra. Sending a heartfelt thanks to the patients participating in our Phase 2 trials for Fragile X syndrome and #Alzheimer’s disease. Hoping for positive outcomes in 2020!

[Tetra Therapeutics @TetraDiscovery]

Read more about EBK, our "rockstar" clinical investigator, Dr. Elizabeth Berry-Kravis at Rush University Medical Center in Chicago and one family's view of participating in the Tetra BPN14770 clinical trial in Fragile X Syndrome.

[FRAXA Research @FRAXAresearch]

A #FragileX #clinicaltrial of a new PDE4D allosteric inhibitor from @TetraDiscovery is nearly complete. Right now there are 3 remaining spots open. Dr. Elizabeth Berry-Kravis at the @RushUniversity Medical Center in Chicago is leading this trial.
https://t.co/W2FK7iaMjZ

[Tetra Therapeutics @TetraDiscovery]

Last week at #CTAD19 we presented findings from a study showing that TNF blocking agents reduce the risk of Alzheimer’s disease in patients with rheumatoid arthritis or psoriasis. #Hope #Alzheimer’s. Read the press release here: https://t.co/O0K5UE25FW

[Tetra Therapeutics @TetraDiscovery]

So pleased to be partnering with @FRAXAresearch on this #clinicaltrial

[FRAXA Research @FRAXAresearch]

A #FragileX #clinicaltrial of a new PDE4D allosteric inhibitor from @TetraDiscovery is nearly complete. Right now there are 3 remaining spots open. Dr. Elizabeth Berry-Kravis at the @RushUniversity Medical Center in Chicago is leading this trial.
https://t.co/W2FK7iaMjZ

[Tetra Therapeutics @TetraDiscovery]

Could TNF blocking agents reduce the risk of #Alzheimer’s disease in patients with rheumatoid arthritis or psoriasis? Find out more during #CTAD19 in San Diego during @TetraDiscovery’s poster session on Friday.

[Tetra Therapeutics @TetraDiscovery]

Looking forward to participating on Tuesday #MIDrugDiscovery @MichBIO Cutting Edge / Drug Discovery & Development - MichBio https://t.co/6IxaHdGto7

[Tetra Therapeutics @TetraDiscovery]

Pleased to be @UsAgainstAlz 2019 National #Alzheimers Summit supporting scientific & legislative progress.

[Tetra Therapeutics @TetraDiscovery]

Latest from CEO Mark Gurney: Can Anti-TNF Drugs Reduce Alzheimer's Risk? https://t.co/d21qP6WhCk

[Tetra Therapeutics @TetraDiscovery]

This #WorldAlzheimersDay2019 we celebrate #clinicaltrials whose #volunteers speed the progress of #research https://t.co/fnzm8TOZjL

[Tetra Therapeutics @TetraDiscovery]

We are now Tetra Therapeutics - https://t.co/bAVIFtm21B

[Tetra Therapeutics @TetraDiscovery]

We can't think of a better way to highlight National Fragile X Awareness day! Fragile X Clinical Trial of PDE4D Inhibitor https://t.co/87NgzsnfJC via @YouTube #ThisisFragileX

[Tetra Therapeutics @TetraDiscovery]

Michigan Angels have made Tetra’s progress possible.

[Ann Arbor SPARK @AnnArborSPARK]

💸The Michigan Angel Community recently released its 2018 angel activity report and the numbers are encouraging! 💸 #AngelInvesting
https://t.co/JBFCQdimfh

[Tetra Therapeutics @TetraDiscovery]

Happy to be a sponsor of @FRAXA @BiotechGames

[FRAXA Biotech Games™ @BiotechGames]

Only in Boston! We are thrilled to facilitate #collaboration in the life science community in greater #boston. We’re all in this together! #MIT @MassBio @MALifeSciences @BosBioXchange @sxbegle @statnews @Xconomy @OvidRx @ZynerbaPharma @TetraDiscovery @Sunovion #biotech